Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2025)

Contineum Therapeutics has reported Interest & Investment Income over the past 3 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $2.0 million for Q4 2025, down 20.49% from a year ago — trailing twelve months through Dec 2025 was $8.2 million (down 7.41% YoY), and the annual figure for FY2025 was $8.2 million, down 7.4%.
  • Interest & Investment Income for Q4 2025 was $2.0 million at Contineum Therapeutics, up from $2.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CTNM hit a ceiling of $2.7 million in Q3 2024 and a floor of $401000.0 in Q1 2023.
  • Median Interest & Investment Income over the past 3 years was $2.0 million (2024), compared with a mean of $1.8 million.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 307.98% in 2024 and later fell 28.6% in 2025.
  • Contineum Therapeutics' Interest & Investment Income stood at $1.8 million in 2023, then soared by 41.23% to $2.5 million in 2024, then dropped by 20.49% to $2.0 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.